Literature DB >> 26556986

Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.

Omar Ramos-Lopez1, Erika Martinez-Lopez1, Sonia Roman1, Nora A Fierro1, Arturo Panduro1.   

Abstract

Liver cirrhosis (LC) is a chronic illness caused by inflammatory responses and progressive fibrosis. Globally, the most common causes of chronic liver disease include persistent alcohol abuse, followed by viral hepatitis infections and nonalcoholic fatty liver disease. However, regardless of the etiological factors, the susceptibility and degree of liver damage may be influenced by genetic polymorphisms that are associated with distinct ethnic and cultural backgrounds. Consequently, metabolic genes are influenced by variable environmental lifestyle factors, such as diet, physical inactivity, and emotional stress, which are associated with regional differences among populations. This Topic Highlight will focus on the genetic and environmental factors that may influence the metabolism of alcohol and nutrients in the setting of distinct etiologies of liver disease. The interaction between genes and environment in the current-day admixed population, Mestizo and Native Mexican, will be described. Additionally, genes involved in immune regulation, insulin sensitivity, oxidative stress and extracellular matrix deposition may modulate the degree of severity. In conclusion, LC is a complex disease. The onset, progression, and clinical outcome of LC among the Mexican population are influenced by specific genetic and environmental factors. Among these are an admixed genome with a heterogenic distribution of European, Amerindian and African ancestry; a high score of alcohol consumption; viral infections; a hepatopathogenic diet; and a high prevalence of obesity. The variance in risk factors among populations suggests that intervention strategies directed towards the prevention and management of LC should be tailored according to such population-based features.

Entities:  

Keywords:  Genomic medicine; Nonalcoholic steatohepatitis; Obesity; Polymorphisms; Risk factors; Viral hepatitis

Mesh:

Year:  2015        PMID: 26556986      PMCID: PMC4631960          DOI: 10.3748/wjg.v21.i41.11552

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  169 in total

1.  Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.

Authors:  O Campollo; M D Martínez; J J Valencia; J Segura-Ortega
Journal:  Subst Use Misuse       Date:  2001-02       Impact factor: 2.164

Review 2.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

3.  -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men.

Authors:  Isabel J Pastor; F Javier Laso; Alfonso Romero; Rogelio González-Sarmiento
Journal:  Alcohol Clin Exp Res       Date:  2005-11       Impact factor: 3.455

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo Castaño; Tomas Fernández Gianotti; Carolina Gemma; Carlos Jose Pirola
Journal:  J Nutr Biochem       Date:  2008-10-15       Impact factor: 6.048

6.  Study of the association between polymorphisms of the COL1A1 gene and HBV-related liver cirrhosis in Chinese patients.

Authors:  Yun-Peng Zhao; Hao Wang; Meng Fang; Qiang Ji; Zai-Xing Yang; Chun-Fang Gao
Journal:  Dig Dis Sci       Date:  2008-06-07       Impact factor: 3.199

7.  Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Kikuko Hotta; Yuichi Nozaki; Hiroki Endo; Takashi Uchiyama; Hironori Mawatari; Hiroshi Iida; Shingo Kato; Koji Fujita; Hirokazu Takahashi; Hiroyuki Kirikoshi; Noritoshi Kobayashi; Masahiko Inamori; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Koichiro Wada; Atsushi Nakajima
Journal:  Liver Int       Date:  2009-03-03       Impact factor: 5.828

Review 8.  Innate immune responses in hepatitis B virus (HBV) infection.

Authors:  Aurelia Busca; Ashok Kumar
Journal:  Virol J       Date:  2014-02-07       Impact factor: 4.099

9.  Nutrition therapy for liver diseases based on the status of nutritional intake.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Manabu Nakashima; Kazuhiro Kotoh; Makoto Nakamuta; Munechika Enjoji
Journal:  Gastroenterol Res Pract       Date:  2012-11-14       Impact factor: 2.260

Review 10.  Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.

Authors:  Seung-Hoi Koo
Journal:  Clin Mol Hepatol       Date:  2013-09-30
View more
  16 in total

1.  Early Detection of Liver Damage in Mexican Patients with Chronic Liver Disease.

Authors:  Rafael Torres-Valadez; Sonia Roman; Alexis Jose-Abrego; Maricruz Sepulveda-Villegas; Claudia Ojeda-Granados; Ingrid Rivera-Iñiguez; Arturo Panduro
Journal:  J Transl Int Med       Date:  2017-03-31

2.  Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality.

Authors:  Hyun-Seok Kim; Xiangjun Xiao; Jinyoung Byun; Goo Jun; Stacia M DeSantis; Han Chen; Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal; Christopher I Amos
Journal:  JAMA Netw Open       Date:  2022-10-03

3.  Escherichia/Shigella, SCFAs, and Metabolic Pathways-The Triad That Orchestrates Intestinal Dysbiosis in Patients with Decompensated Alcoholic Cirrhosis from Western Mexico.

Authors:  Tonatiuh Abimael Baltazar-Díaz; Luz Alicia González-Hernández; Juan Manuel Aldana-Ledesma; Marcela Peña-Rodríguez; Alejandra Natali Vega-Magaña; Adelaida Sara Minia Zepeda-Morales; Rocío Ivette López-Roa; Susana Del Toro-Arreola; Erika Martínez-López; Adriana María Salazar-Montes; Miriam Ruth Bueno-Topete
Journal:  Microorganisms       Date:  2022-06-16

4.  CD36 genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection.

Authors:  Omar Ramos-Lopez; Sonia Roman; Erika Martinez-Lopez; Nora A Fierro; Karina Gonzalez-Aldaco; Alexis Jose-Abrego; Arturo Panduro
Journal:  World J Hepatol       Date:  2016-09-08

5.  Sweet Taste Receptor TAS1R2 Polymorphism (Val191Val) Is Associated with a Higher Carbohydrate Intake and Hypertriglyceridemia among the Population of West Mexico.

Authors:  Omar Ramos-Lopez; Arturo Panduro; Erika Martinez-Lopez; Sonia Roman
Journal:  Nutrients       Date:  2016-02-19       Impact factor: 5.717

6.  Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model.

Authors:  Daniel Cervantes-Garcia; Adriana Guadalupe Cuellar-Juarez; Gissela Borrego-Soto; Augusto Rojas-Martinez; Liseth Rubi Aldaba-Muruato; Eva Salinas; Javier Ventura-Juarez; Martin Humberto Muñoz-Ortega
Journal:  Mol Med Rep       Date:  2017-10-12       Impact factor: 2.952

7.  Estimation of utility weights for major liver diseases according to disease severity in Korea.

Authors:  Minsu Ock; So Yun Lim; Hyeon-Jeong Lee; Seon-Ha Kim; Min-Woo Jo
Journal:  BMC Gastroenterol       Date:  2017-09-05       Impact factor: 3.067

8.  miR-200c Accelerates Hepatic Stellate Cell-Induced Liver Fibrosis via Targeting the FOG2/PI3K Pathway.

Authors:  Tengfei Ma; Xiuqin Cai; Zifeng Wang; Li Huang; Chang Wang; Songshan Jiang; Yunpeng Hua; Quentin Liu
Journal:  Biomed Res Int       Date:  2017-06-13       Impact factor: 3.411

9.  Vitamin D Deficiency and Its Relationship with Child-Pugh Class in Patients with Chronic Liver Disease.

Authors:  Zubia Jamil; Sharmin Arif; Anum Khan; Asghar Aurangzeb Durrani; Nayyar Yaqoob
Journal:  J Clin Transl Hepatol       Date:  2018-02-01

10.  The Power of Resolution: Contextualized Understanding of Biological Responses to Liver Injury Chemicals Using High-throughput Transcriptomics and Benchmark Concentration Modeling.

Authors:  Sreenivasa C Ramaiahgari; Scott S Auerbach; Trey O Saddler; Julie R Rice; Paul E Dunlap; Nisha S Sipes; Michael J DeVito; Ruchir R Shah; Pierre R Bushel; Bruce A Merrick; Richard S Paules; Stephen S Ferguson
Journal:  Toxicol Sci       Date:  2019-06-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.